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INTRODUCTION
The British Thoracic Society (BTS) launched a Global Health Group at the 2019 Winter Meeting 
in Partnership with the Pan African Thoracic Society (PATS). This was met with an overwhelming 
level of interest and a symposium on Africa’s Respiratory “Big Five” was proposed in response 
and to build on the momentum behind the Global Health Group. Whilst 2020 turned out to 
be a rather different year to that expected when we convened at the end of 2019, we continued 
our work to the best of our ability and delivered our symposium at the rescheduled BTS Winter 
Meeting in February 2021 in a virtual format. We were delighted by the level of interest in the 
symposium which had 226 attendees. We were deeply grateful to the BTS for extending an offer 
of free registration and attendance at the full Winter Meeting to all PATS members. This paper 
offers a summary of the symposium focused on research priorities relating to the topics discussed 
(pneumonia in the under fives, post-TB lung disease, ambient air pollution (AP), and respiratory 
disease and non-communicable respiratory disease across the life-course). It then links this to 
PATS Methods in Epidemiologic Clinical and Operations Research (MECOR) in the hope this 
will stimulate new ideas for PATS MECOR student projects and possible projects that BTS and 
PATS members could do together.
ABSTRACT
The British Thoracic Society (BTS) launched a Global Health Group in the winter of 2019 in partnership with the 
Pan African Thoracic Society. This key meeting generated a lot of interest and areas of mutual benefit. Due to the 
overwhelming interest at the 2019 meeting, a virtual offering of the BTS Winter meeting February 2021, included 
a symposium by the Global Health Group on Africa’s Respiratory “Big Five.” The Winter meeting was free for 
PATS members and symposium had an excellent attendance, covering the following areas: Pneumonia in the 
under 5, impact of air pollution on lung health, post-TB lung disease, and non-communicable respiratory disease 
across the life course. This paper is a summary of the symposium and seeks to address research priority areas for 
lung health research on the African continent.
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PNEUMONİA İN UNDER-FİVES
For decades, pneumonia has persistently remained the 
biggest killer of children but is still forgotten. In 2018, 
an estimated 802,000 children age <5 years died from 
pneumonia. Low- and middle-income countries, especially 
those in sub-Saharan Africa and South-East Asia (SEA), 
are disproportionately affected, with up to 99% of the 
pneumonia cases and deaths occurring in these countries.[1,2] 
Between 2000 and 2018, pneumonia deaths reduced by 54% 
but this progress is slower compared to reductions in other 
childhood infectious diseases such as measles (81%), HIV 
(67%), diarrhea (64%), and malaria (59%).[3]
Pneumonia deaths are largely preventable. The integrated 
Global Action Plan for Pneumonia and Diarrhea aims to 
reduce pneumonia deaths to less than 3/1000 live births 
globally.[3] However, given the current trends, the world will not 
meet this target. Many countries in Africa including Nigeria, 
Democratic Republic of Congo, and Tanzania have a high 
pneumonia burden with less than 10% annual rate of reduction 
in pneumonia deaths.[4] The poorest and most vulnerable 
children are at greatest risk; therefore, pneumonia is a marker 
of health inequities and multiple deprivations. Furthermore, 
recurrent pneumonia in early childhood increases the risk of 
developing chronic lung diseases such as asthma and chronic 
obstructive pulmonary disease (COPD).[5,6]
Interventions to prevent pneumonia deaths include; (1) 
protecting children from getting pneumonia through 
adequate nutrition, (2) comprehensive immunization against 
pneumococcus, measles, Haemophilus influenzae type b, 
pertussis (whooping cough), and influenza, (3) avoiding tobacco 
smoke exposure and reducing exposure to indoor AP, and (4) 
prevention and treatment of HIV. Children who get pneumonia 
can also be saved if prompt and appropriate treatment with 
antibiotics, referral to hospital, and oxygen therapy when 
needed are provided. However, despite these interventions, 
pneumonia deaths remain unacceptably high and the problem 
is multifactorial. Africa has a high burden of risk factors for 
pneumonia. Up to 35% of deaths in under-fives are associated 
with malnutrition, and the case-fatality rate among severely 
malnourished children with pneumonia ranges between 17 and 
37.6%.[1,7-9] Less than 10% of children are exclusively breastfed for 
4–6 months.[10-12] Vaccines such as the pneumococcal conjugate 
vaccine (PCV) are very effective in prevention of pneumonia. In 
Malawi, the introduction of the 13-valent PCV led to a decline 
of hypoxemic pneumonia and overall childhood deaths by 47% 
and 36%, respectively,[13] while in The Gambia, the incidence of 
invasive pneumococcal disease decreased by 55%.[14] However, 
one in five children in Africa does not receive the vaccines they 
need. Half of the pneumonia deaths are attributable to AP. In 
Africa, 95% of the children <5 years are exposed to high levels 
of AP largely from use of biomass for cooking[15] Interventions 
to reduce household AP through use of cleaner biomass fuelled 
cookstoves have been tried, but these have not significantly 
reduced the AP and as such, no significant impact on the 
incidence of childhood pneumonia.[16] The WHO/UNICEF 
Integrated Management of Childhood Illnesses and integrated 
Community Case Management strategies have played a big role 
in reducing pneumonia deaths in children.[17] However, access 
to care remains a challenge with only two-thirds of children 
who need antibiotics accessing them. Hypoxemia is a strong 
predictor of pneumonia deaths and using clinical evaluation 
alone is not sufficient to identify children with hypoxemia thus 
the need for widespread use of pulse oximetry.[18] Access to pulse 
oximetry and reliable oxygen delivery systems is a big challenge 
especially in remote health facilities.[18,19]
Previously, Streptococcus pneumoniae and Haemophilus 
influenzae were the major pathogens for severe pneumonia 
requiring hospitalization, but viruses are emerging as the 
leading cause of severe pneumonia. The Pneumonia Etiology 
Research Child Study[20] and the Drakenstein Child Health 
Study in South Africa have shown that RSV is responsible for 
up to 30% of the pneumonia cases, and that it was associated 
with a 3-fold risk of the lower respiratory tract infection 
(LRTI) thus increasing the risk of poor lung function.[21]
We know what works, but to accelerate the decline in 
pneumonia deaths, we must deliver innovative and 
comprehensive strategies to implement evidence-based 
interventions. The three pillars of Primary Health Care; 
Integrated Health Services, Multisectoral policy and action, 
and Empowered people and communities have been 
identified as the foundation for ending preventable child 
deaths from pneumonia. It is envisaged that pneumonia 
deaths can be substantially reduced if AP, nutrition, 
immunization, and case management including effective 
referral systems are comprehensively addressed. Despite 
being the leading cause of childhood deaths, pneumonia 
receives less development assistance than other diseases 
like HIV and malaria. There is need to increase allocation 
of funds to pneumonia control. Finally, accountability and 
engagement of communities and education are critical areas 
that will support and sustain pneumonia control strategies. 
Three suggested research priorities
•	 Innovative ways to strengthen, accelerate, and sustain 
available interventions for pneumonia control
•	 Simple and cheap point of care diagnostics for 
pneumonia
•	 Explore mHealth and eHealth platforms.
POST-TB LUNG DİSEASE
The global burden of TB disease remains unacceptably high 
with an estimated 10 million incident cases and 1.4 million 
deaths in 2019.[22] However, survival is increasing and it is 
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now thought that 85% of TB patients survive to treatment 
completion, with an estimated 155 million TB survivors alive 
globally today, the majority of whom are located in the SEA, 
Western Pacific, and African WHO regions.[23] However, 
targets set by the international TB community and National 
TB programs, and estimates of TB-related morbidity remain 
focused on the period of TB disease and treatment only, 
with an assumption that the health of TB survivors returns 
to normal at TB treatment completion. In the current model 
of care patients are discharged at treatment completion with 
no rehabilitation, little health-care advice, and no further 
routine review. However, it is increasingly clear that for 
many patients, the long-term impact of TB disease on is 
marked.[24,25]
Post-TB lung disease (PTLD) is a key form of post-TB 
morbidity, alongside other forms of physical, psychosocial, 
and economic sequelae of disease. Several cross-sectional 
studies have demonstrated an association between previous 
TB disease and reduced lung function: Routine spirometry 
data from miners in South Africa shows that adults who had a 
previous episode of TB disease had forced expiratory volume 
(FEV1) and forced vital capacity (FVC) volumes which were 
on average 180 ml and 120 ml lower that that seen in miners 
with no history of TB disease;[26] data from Malawi suggest 
that 3-years after TB treatment completion, 12.5% of PTB 
survivors had a low-FVC pattern of spirometry, and 15.8% 
had obstruction; findings from the burden of obstructive lung 
disease study showed that amongst 14,050 adults ≥40 years, 
drawn from 19 global study sites, a self-reported a history 
of TB disease was associated with both air-flow obstruction 
(aOR 2.51, 1.83–3.42) and spirometric restriction (aOR 2.13, 
1.42–3.19);[27] and a recent cohort study of adult TB-survivors 
in South Africa suggests a high burden of gas trapping and 
impaired gas transfer amongst PTB survivors 1-year after 
TB-treatment completion.[28] A high burden of PTLD has 
also been demonstrated on imaging studies: Work in Malawi 
showed residual bronchiectasis and lobar parenchymal 
destruction in 44% and 9% of PTB survivors, respectively,[29] 
and these findings are consistent with systematic review data 
from elsewhere.[30] Marked heterogeneity in the patterns 
and extent of PTLD, and the extent to which the airways, 
parenchyma, pleura are affected by TB disease is observed 
across studies. This heterogeneity was discussed at the first 
international post-TB symposium held in 2019 at which 
a broad minimum case definition for PTLD was reached: 
Evidence of chronic respiratory abnormality, with or without 
symptoms, attributable at least in part to the previous 
tuberculosis.[31]
Understanding of the longer-term impact of PTLD on patient 
outcomes is growing. Prospective data tracking spirometry 
over time after PTB treatment completion suggests some 
recovery within the first 6–12 months after treatment 
completion, but shows that this recovery is incomplete. 
Similar findings are seen with data on symptoms, with a 
reduction in the frequency and prevalence of respiratory 
symptoms including cough and breathlessness from TB 
treatment completion to 6- and 12-months later, but still 10–
20% of patients experiencing symptoms which affect daily 
activities or work in the Malawian cohort described above 
by 1-year.[29] Cross-sectional data from post-TB patients 
surveyed in one Indian setting identified breathlessness in 
almost a third of PTB survivors located 14–18 years after 
treatment completion.[32] It is possible that these ongoing 
post-TB respiratory symptoms and abnormal spirometry 
are associated with loss of work by 1 year after TB treatment 
completion.[33]
Other potential outcomes of concern amongst PTB survivors 
include recurrent TB disease, superadded respiratory 
infections, and increased mortality. Former TB patients are 
at high risk of recurrent TB disease, including both relapse 
and reinfection.[34,35] Rates of recurrence among PTB patients 
are three to four-fold higher than incidence rates seen in 
the general population in settings such as South Africa,[36,37] 
in both HIV-infected and HIV-negative adults.[37] However, 
the extent to which PTLD acts as a risk factor for disease 
recurrence remains unclear. Similarly, adults previously 
treated for TB disease have an increased standardized 
mortality rate for all-cause mortality compared to TB naïve 
adults, but the contribution of PTLD to long-term mortality 
remains unclear.[38] Although superimposed respiratory 
infections are observed in those with severe PTLD and 
destroyed lung,[39,40] the incidence and microbiology of these 
infections remain poorly described, and few primary data are 
available on the burden of fungal disease in LMICs.
Further research into approaches for prevention and 
management of PTLD are required. A more detailed 
understanding of the host, pathogen and environmental 
drivers of disease heterogeneity will be key to preventing 
TB patients from developing PTLD.[41,42] For those with 
established disease, evidence is needed for programmatic 
interventions which could be implemented in decentralized 
low-income settings to improve patient outcomes. Pulmonary 
rehabilitation holds much promise, with pilot work showing 
improvement in exercise capacity and quality of life among 
PTB survivors, and randomized trials are ongoing.[43,44] The 
development of digital rehabilitation tools in the COVID-19 
era has the potential to increase accessibility.[45] More data 
are needed to determine whether post-TB obstructive 
airways disease should be managed similarly to tobacco 
related airway obstruction, and what the role of inhaled 
bronchodilators and steroids might be.[46] Crucially, the need 
to address the broader social determinants of health and 
disability must not be forgotten when thinking of strategies 
for post-TB care.[47,48]
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Three suggested research priorities
•	 Collection of data on post-TB morbidity within broader 
TB research studies, including those focused on active 
case finding and TB treatment regimens
•	 Basic science and epidemiology research to understand 
the host, pathogen, and environmental determinants 
of the heterogeneity observed in PTLD, and to inform 
strategies for prevention
•	 Qualitative work to understand patient experiences and 
priorities for post-TB care in LMICs.
AİR POLLUTİON AND RESPİRATORY DİSEASE 
İN AFRİCA
AP has been deemed a “silent public health emergency” 
by the World Health Organization (WHO), akin to active, 
and passive tobacco exposure. Globally, more than 90% of 
the world’s population live in areas with AP above WHO 
limits, with more than 7 million deaths attributed to AP 
annually.[49] AP affects LMIC disproportionately especially 
in Africa where there are a number of colliding epidemics, 
including a high burden of exposures, infectious diseases, 
and increasingly recognized non-communicable diseases.[50]
AP encompasses both indoor (household AP from the use 
of dirty-burning fuels for energy) and outdoor (generated by 
traffic, industry, and agriculture) sources.[51] The impact of AP 
on respiratory health begins early and continues throughout the 
life-course. Antenatal exposure to AP is not only associated with 
an increased risk of respiratory infections[52] but also impacts on 
lung development and growth with lung function impairments 
described in early life.[53] Life-long respiratory impacts include 
the irritant effects of AP exposure (cough, increased phlegm, 
bronchial hyperresponsiveness, and infective exacerbations), 
increased risk of asthma symptoms and exacerbations, 
accelerated decline in lung function, and increased morbidity 
and mortality from COPD and lung cancer.[54]
There is limited epidemiological AP data from Africa and 
where data are available, measured AP levels are 10 to 20-fold 
higher than acceptable WHO thresholds,[50] and a leading 
risk factor for LRTI morbidity and mortality, especially 
in children.[55] Further, intervention studies to reduce AP 
exposure, in particular household AP, through the use of 
cleaner burning cookstoves, have found that while there was 
some reduction in AP exposure,[56] a single intervention alone 
did not reduce LRTI incidence significantly, highlighting the 
need for a multi-prong intervention approach.[16]
The COVID-19 pandemic has further highlighted the social 
disparities in health outcomes, especially in LMIC settings. 
The implementation of “lockdown” policies by many 
countries to curb the spread of SARS-COV2 infection saw 
significant reductions in global outdoor AP. However, for 
many people with sub-optimal living conditions prevalent in 
many African LMIC, confinement to homes only increased 
the exposure to indoor environmental exposures.[57]
While addressing AP exposure requires a multi-sectorial 
approach that should be spearheaded at government 
level, the role of the health care worker (HCW) should 
not be underestimated. HCW need to be informed on 
AP and consider it as a risk factor for respiratory diseases; 
participate in research to understand the impacts of AP 
exposure; prescribe simple, translational solutions to affected 
families that can reduce AP exposures; educate colleagues 
and students on the risks associated with AP exposure 
by including in teaching and curricula; and advocate for 
solutions to other sectors, decision, and policy makers.[58]
Three suggested research priorities
•	 Robust African epidemiological AP data that are 
representative of all countries/regions in Africa
•	 Longitudinal exposure health outcome data that utilize 
validated exposure and outcome assessments, beyond 
self-reported
•	 Effective and affordable interventions to reduce AP 
exposure that may require a multi-pronged approach.
NON-COMMUNİCABLE RESPİRATORY 
DİSEASE (ASTHMA AND COPD) ACROSS THE 
LİFE-COURSE
The environment is one of the key determinants of outcomes, 
and this is heterogeneous within and between countries; there 
are islands of affluence in LMICs and poverty in high income 
settings (HICs). Diseases given the same umbrella label may 
be phenotypically different in different environments;[59] for 
example, in Brazil, ascaris burden was more closely related to 
asthma than was atopy.[60] Most life course information has 
come from HIC birth cohorts. Asthma and COPD start early 
in childhood.[61,62] Adverse intra-uterine events set up the baby 
for long-term impaired respiratory health. Most studied is 
smoking in pregnancy, and the outcomes are low birth weight 
and prematurity; abnormal lung structure; abnormal immune 
function setting the child up for early respiratory infection; 
and sensitization to the effects of subsequent exposures in 
adult life. Children with asthma have airflow obstruction 
age 7 years, and 40% of this is determined antenatally.[63] 
Impaired lung function shortly after birth strongly associates 
with altered lung structure in the third decade, and asthma in 
the fourth decade of life.[64] Subsequent growth trajectories in 
the main show that lung function tracks into late middle age 
without catch-up growth.[65-68] Lung function decline after age 
20–25 years relates most consistently to early life disadvantage 
rather than adult smoking,[69,70] dangerous though the latter is 
in other ways. COPD risk is greatest in those who fail to reach 
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the normal lung function plateau in their early 20s, but is also 
seen in those with accelerated decline.[71]
There are important differences reported from Africa 
compared with HICs. There are significantly higher 
prevalences of smoking in pregnancy, maternal HIV 
infection and alcohol use, household benzene exposure, and 
psychological stresses such as post-traumatic stress syndrome 
and intimate partner violence.[72,73] The burden of infection 
is very high, even in asymptomatic children (median five 
organisms from a nasopharyngeal swab).[74] By contrast 
with Perth,[75] Australia, severe LRTI was an independent 
risk factor for 1 year lung function.[5] Vertical transmission 
of HIV was virtually totally prevented in Drakenstein, but 
infants born to HIV positive mothers had early abnormal 
lung function.[76] In HIC, impaired spirometry is associated 
not merely with poor respiratory outcomes, but also 
premature cardiovascular and metabolic morbidity and 
mortality.[77] Whether this is the case in Africa is unknown 
but seems likely.
In summary, if LMICs (and HICs) want to prevent asthma and 
COPD, they must start by protecting the fetus and the newborn. 
It is no use focusing on adult life, or distributing medicines 
like inhaled corticosteroids, laudable as this is, if fundamental 
changes are to be made. Early insults are not merely harmful in 
themselves, but set the baby up to vulnerability to later adverse 
events. Africa has novel early risk factors including pollutants, 
HIV positive mothers, and severe adverse physical and 
psychological circumstances. Africa also has novel second hits 
including tuberculosis and HIV, both of which have long-term 
respiratory sequelae, with the scene likely set for sequelae by 
early life deprivation. We need effective legislation, which we 
know works, to protect these vulnerable populations if LMIC 
lung health across the life course is to improve. Sadly, it is too 
late for preventative approaches for the present generation.
Three suggested research priorities
•	 What interventions can be used to reduce environmental 
pollution, specifically within the home, including 
reducing smoking and vaping?
•	 What interventions other than immunizations can be 
put in place to reduce the burden of infection in LMICs?
•	 How can women in particular be supported to prevent 
exposure to psychological stress including intimate 
partner violence?
PATS MECOR AND OPPORTUNİTİES TO 
ADDRESS RESEARCH GAPS FOR AFRİCA’S BİG 5
The PATS MECOR program is well positioned to address 
the research needs that could improve outcome and drive 
policy change regarding Africa’s big 5. Since 2007, PATS in 
partnership with the American Thoracic Society through 
the MECOR program has trained 254 students from across 
22 African countries in the conduct of research. The annual 
week-long course led predominantly by African faculty 
is delivered at three levels with subsequent continuous 
mentorship post-course. The course has gone further and 
also delivers quality training on spirometry and air quality 
measurement to equip the students for the conduct of high 
impact research.
The aim of the PATS MECOR program has been to address 
global respiratory needs with focus on the local contexts 
where our students live and work. We are aware that the time 
has come for Africans to be at the forefront of identifying, 
highlighting and seeking solution to their local challenges. 
The scope of the program that ranges from measurement of 
the burden of disease to advanced clinical research training, 
to manuscript and grant writing provides an excellent 
opportunity to build the needed capacity to confront the 
research gaps regarding Africa’s Big 5.
We analyzed our student database for students who enrolled 
in the PATS MECOR course from 2015 to 2020, to review the 
throughputs of the course [Tables  1 and 2]. Data collected 
included participant demographics, country of origin, number 
who completed each level and number of students who 
received small grants for research projects. For the students 
who completed all three levels of the course, we conducted 
a PubMed search of all publications linked to the MECOR 
student and categorized these into pre-MECOR and post-
MECOR research outputs. From the research outputs, the 
most prolific researchers who published were those linked into 
national research or governmental agencies with linkages to 
larger international research collaborative work. The university 
researchers collaborated with MECOR students and faculty in 
publications and tended to also be first and last authors.
Table 1: Summary table of PATS MECOR students and progress 
from 2015 to 2019 (n=124).
Characteristic Number/%
Age (mean in years/range) 38.5¶ (29–
60)
Gender (male) 85 (68.0) 
Number of countries 17
Completed Level 1 124 (100.0)
Completed Level 2 58 (46.8)
Completed Level 3 20 (16.1)
Number of grants awarded 21 
Number of grant recipients 20* 
Grant recipients completed L3 5 (25.0)
Years between L1 and L2 (Mean 
age in years/range)
1.6 (1–8)
Years between L2 and L3 (Mean 
age in years/range)
1.5 (1–3)
¶Age available in only 91 students; *(1 student received 2 small grants)
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About a quarter of new cases of TB globally are reported in 
Africa, yet the burden of post-TB lung disease in Africa is not 
well documented.[78] The implication of absent data is that 
health system needs other than programmatic TB treatment 
are not prioritized and no clear pathway for subsequent care 
exists. These are underpinnings for expansion of our research 
focus at PATS MECOR toward quantifying this burden which 
dovetails into exploring care pathways, effective modalities of 
treatment and the conceptualization and testing of potential 
preventive strategies.
The now apparent high burden of asthma in Africa brings 
to the fore the emerging research needs for primordial, 
primary and secondary prevention.[79] We also need research 
that strengthens health systems across Africa to deliver 
appropriate asthma care. Harnessing previously successful 
strategies used in improving access to care in Africa such 
as task shifting, free access to medications, community 
outreaches, and free testing are worth exploring.[80]
Lung function data for African children which sets the stage 
for future pulmonary, cardiovascular, and all-cause mortality 
are generally lacking. These data are needed to drive policy 
regarding household cooking fuels, siting of schools, and 
lung function testing as part of regular growth screening.[81] 
PATS MECOR students are well equipped to lead this charge.
Non-tobacco associated COPD which is more prevalent in Africa 
is an area that needs both epidemiologic and clinical data.[82] The 
risk factors need to be teased out together with the clinical profile, 
disease course, and response to available treatment modalities. As 
Africa improves its immunization coverage to reduce childhood 
pneumonias, there is also need to conduct research that improves 
outcome for those who develop pneumonia. 
Three suggested research capability building priorities
1. Create African led and delivered research hubs and 
centers of excellence that will provide supportive research 
environments for African clinicians and scientists
2. Develop research capacity building opportunities for 
graduates of programs like PATS MECOR including 
Masters, PhD Fellowships, and post-doctoral training 
posts
3. Monitor and evaluate the outcomes of PATS MECOR 
and other research capability building programs to 
identify areas for strengthening these and learn from 
barriers and facilitators of academic career development 
in Africa.
CONCLUSİON
There is a clear need to keep focused on the major causes of 
morbidity and mortality across the life-course in Africa and 
persevere with our efforts to make a difference despite the 
desperately difficult circumstances we all find ourselves in at 
the moment. COVID-19 was not a known disease when we 
launched the BTS Global Health Group in early December 
2019. This symposium deliberately kept its original focus as 
COVID-19 has already taken so much from so many and 
that sadly includes resources from Africa’s respiratory big 
five. Although the coming years will undoubtedly be difficult, 
initiatives that bring us together including our collaboration 
between PATS and the BTS Global Health Group offer much 
needed hope that we can and will make a difference.
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